Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of Acrivon Therapeutics (NASDAQ:ACRV) in a research report sent to investors on Thursday, Benzinga reports. The brokerage currently has a $20.00 price target on the stock.

A number of other equities research analysts have also issued reports on ACRV. JMP Securities reaffirmed a market outperform rating and set a $14.00 price objective on shares of Acrivon Therapeutics in a report on Monday, April 1st. BMO Capital Markets reiterated an outperform rating and issued a $18.00 price target on shares of Acrivon Therapeutics in a report on Monday, April 1st. Finally, LADENBURG THALM/SH SH dropped their price objective on shares of Acrivon Therapeutics from $18.00 to $14.00 and set a buy rating for the company in a report on Friday, April 5th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, Acrivon Therapeutics has an average rating of Buy and a consensus target price of $22.63.

Acrivon Therapeutics Price Performance

Shares of NASDAQ ACRV opened at $8.46 on Thursday. The stock has a market cap of $191.53 million, a PE ratio of -3.10 and a beta of 1.94. Acrivon Therapeutics has a 1 year low of $3.19 and a 1 year high of $14.30. The firm has a fifty day moving average price of $6.65 and a 200-day moving average price of $5.35.

Acrivon Therapeutics (NASDAQ:ACRV) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.14). On average, research analysts expect that Acrivon Therapeutics will post -3.16 EPS for the current year.

Insider Transactions at Acrivon Therapeutics

In related news, major shareholder Perceptive Advisors Llc purchased 2,353,000 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The stock was bought at an average price of $8.50 per share, for a total transaction of $20,000,500.00. Following the completion of the transaction, the insider now owns 5,360,858 shares in the company, valued at approximately $45,567,293. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.30% of the company’s stock.

Hedge Funds Weigh In On Acrivon Therapeutics

An institutional investor recently raised its position in Acrivon Therapeutics stock. Exchange Traded Concepts LLC raised its position in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) by 34.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,289 shares of the company’s stock after acquiring an additional 3,370 shares during the period. Exchange Traded Concepts LLC owned approximately 0.06% of Acrivon Therapeutics worth $65,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.